- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S4550
| Related Targets | Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease |
|---|---|
| Other Bacterial Products | Berberine BTZ043 Racemate Teicoplanin Ornidazole Skatole Berberine Sulfate Pipemidic acid Ceftiofur PBTZ169 Aminothiazole |
|
In vitro |
DMSO
: 37 mg/mL
(196.57 mM)
Water : 37 mg/mL Ethanol : 37 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 188.22 | Formula | C9H16O4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 123-99-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Nonanedioic acid, Finacea, Azelex, Anchoic acid | Smiles | C(CCCC(=O)O)CCCC(=O)O | ||
| In vitro |
AZ(Azelaic acid) combined with taurine (Tau) show more inhibitory effects in melanocytes than the treatment of this compound alone. This combination inhibits the melanin production and tyrosinase activity of B16F10 melanoma cells without significant cytotoxicity. Also inhibitory effects after treatment with these combined chemical are stronger than this acid alone on melanogenesis.
|
|---|---|
| In vivo |
Azelaic acid exhibits an anti-atherogenic effect. Its athero-protective effect is not related to changes in plasma lipid content. This compound supplementation decreases the level of CD68 macrophage marker by 34% (p<0.05).
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.